268 related articles for article (PubMed ID: 28494536)
1. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
3. Concordance of Carcinoembryonic Antigen Ratio and Response Evaluation Criteria in Solid Tumors as Prognostic Surrogate Indicators of Metastatic Colorectal Cancer Patients Treated with Chemotherapy.
Huang SC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Lin CC; Jiang JK; Chang SC
Ann Surg Oncol; 2015 Jul; 22(7):2262-8. PubMed ID: 25586242
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
5. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
6. Negative CEA values in metastatic colorectal carcinoma and the likelihood of complete chemotherapy response.
Tomasevic Z; Jelic S; Nikolic L; Filipovic I; Stamatovic L; Radosavljevic D
Int J Biol Markers; 2003; 18(1):28-32. PubMed ID: 12699060
[TBL] [Abstract][Full Text] [Related]
7. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases.
van Kessel CS; Samim M; Koopman M; van den Bosch MA; Borel Rinkes IH; Punt CJ; van Hillegersberg R
Eur J Cancer; 2013 Jul; 49(11):2486-93. PubMed ID: 23692811
[TBL] [Abstract][Full Text] [Related]
8. Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases.
Neofytou K; Giakoustidis A; Neves MC; Morrison D; Giakoustidis D; Khan AZ; Stebbing J; Mudan S
Langenbecks Arch Surg; 2017 Jun; 402(4):599-605. PubMed ID: 27043945
[TBL] [Abstract][Full Text] [Related]
9. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
10. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
12. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
13. The role of half-life of carcinoembryonic antigen (CEA) in prognosis prediction of colorectal cancer patients with preoperatively elevated CEA.
Yuan SQ; Zhou ZW; Wan DS; Chen G; Lu ZH; Wang GQ; Pan ZZ
Ai Zheng; 2008 Jun; 27(6):612-7. PubMed ID: 18570735
[TBL] [Abstract][Full Text] [Related]
14. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
[TBL] [Abstract][Full Text] [Related]
15. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
Chiu KWH; Lam KO; An H; Cheung GTC; Lau JKS; Choy TS; Lee VHF
BMC Cancer; 2018 Jul; 18(1):776. PubMed ID: 30064385
[TBL] [Abstract][Full Text] [Related]
17. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
Strimpakos AS; Cunningham D; Mikropoulos C; Petkar I; Barbachano Y; Chau I
Ann Oncol; 2010 May; 21(5):1013-9. PubMed ID: 19861580
[TBL] [Abstract][Full Text] [Related]
18. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
[TBL] [Abstract][Full Text] [Related]
19. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
[TBL] [Abstract][Full Text] [Related]
20. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
